Key Takeaways
- Landmark year, strong Q4: FY25 PAT grew 39% and Q4 revenue jumped 43%, driven by volume growth, cost efficiencies and a multi-year strategy of scale and backward integration.
- Backward integration is the margin story: A INR150 crores investment in backward integration is set to materially improve margins starting Q2 FY26, with revenue contribution also beginning to flow from that quarter.
- Ibuprofen scale-up is a major growth lever: The company launched Asia's largest ibuprofen block, is taking market share from a large MNC, and targets nearly 5,000 tons of volume in FY26, more than doubling FY25 output.
- Inventory is elevated but has a plan: High inventory is tied to high-volume commodity products requiring ready stock; management plans to reduce it, including liquidating INR40 crores of slow-moving HCQ inventory in the next 2-3 months.
- What to watch next quarter: The pace of backward integration margin gains from Q2, ibuprofen volume ramp-up toward the 5,000-ton target, and execution on the new INR250 crores capex plan.
Backward Integration & Margin Expansion
- Margin mechanics: Full-year gross margins improved 330 bps, with ~60% of the gain from product mix and ~30% from backward integration; the remaining ~10% was not accounted for by management.
- Volume-category focus: 80% of backward integration efforts target high-volume categories like anti-diabetic and anti-epileptic segments, where cost pressure is most acute; low-volume APIs carry decent margins and receive limited focus.
- Q2 inflection point: Revenue and margin benefits from last year's backward integration capex will start factoring in from Q2 FY26, with the percentage contribution to gross margins expected to be much higher in FY26.
- Validation underway: The vertical integration block setup is complete and validation batches are currently being taken; all necessary licenses and approvals are in hand for commercial production of key intermediates to begin this quarter.
- FY26 margin target: Management anticipates around 20% growth in margins for FY26 on a conservative basis, aiming to expand EBITDA margins by 20%.
Potluri: "So actually, it is mostly the volume categories, like 80% major focus will be on the volume category because that's where the cost pressure is, on the volume ones, like some of the anti-diabetic segment is a critical one and anti-epileptic is one segment we're currently looking at."
Ibuprofen: Scale, Share & Stabilization
- Capacity leadership: The company launched Asia's largest dedicated and automated production block for ibuprofen, positioning it among India's top producers.
- Volume trajectory: Ibuprofen volume reached 2,200 MT in FY25, with a target of close to 5,000 tons in FY26; value growth was 22% in the quarter.
- Market share gains: The company is taking share from a large MNC competitor based on pricing, having launched the product 1.5 years ago; it expects to increase its regulated-market share from the current 40%, with U.S. customer approvals coming one by one through validation batches, stability studies, PAS filings and commercial approvals.
- Price stabilization: Ibuprofen prices have stabilized after a one-year downtrend, holding steady since last quarter.
Inventory: Elevated but Manageable
- Why inventory is high: High-volume commodity products like ibuprofen, tenofovir and sitagliptin require 4-5 days of lead time for orders, making sufficient stock essential to avoid losing business; the current product mix inherently demands higher inventory than in the past.
- Slow-moving component: Of the elevated inventory, INR40 crores is slow-moving, including HCQ; management clarified HCQ is not a COVID product but a regular one where U.S. customers have already filed and anticipate launch in 2-3 months, enabling planned liquidation.
- Reduction plan: Inventory will definitely come down in the coming year, but not to levels seen 3-4 years ago because the current product portfolio structurally requires higher stock.
- No write-offs expected: Management stated there is no written-off inventory, describing the slow-moving portion as inventory awaiting liquidation rather than impairment, though it did not directly address a question about potential future write-offs.
Potluri: "The reason for the high inventory that we are currently maintaining... we have some high-volume products that we are currently moving in terms of volumes, like, for example, ibuprofen, which is high-volume product. And also, we have some old products where we are sitting on some inventory like HCQ... But definitely, in the next coming year, we have plans to reduce our inventory level. It will definitely come down."
Segment & Product Performance
| Segment | Trend | Commentary |
|---|---|---|
| Anti-inflammatory | ▲ Strong | Key growth driver for the full year, supported by ibuprofen scale-up and market share gains. |
| ARV | ▲ Strong | Good traction alongside anti-inflammatory as a primary revenue driver. |
| Anti-epileptic | ▲ Fastest growth | Grew 106%, driven by strong demand and expanded market access. |
| Anti-diabetic | ▬ Modest growth | Grew around 5% in value despite price softening; patents went off in Europe in 2025 but the company retained market share and volume. |
- New customer wins: In FY25, the company onboarded several large clients across its API portfolio in regulated markets, with meaningful scale-up in key molecules.
- Pipeline direction: Management is building a pipeline across existing therapeutic categories and new ones that are attracting good interest.
Capex & Asset Efficiency
- New capex approved: The board approved INR250 crores of capex over the next 18 months for expansion in existing and new products, covering high-volume and high-value APIs as well as the CMO business; this will add new blocks to increase volumes of the existing product mix and introduce new products.
- SMS Peptides investment: A separate INR10 crores investment in SMS Peptides Private Limited was approved, to be executed in one or more tranches.
- Asset turnover ambition: Current asset turnover stands at 0.67, within the 0.6 to 0.7 range management cites for comparable peers; the company is targeting an asset turnover of 1, which management describes as a very aggressive number.
Potluri: "See, the target is one, to be honest with you. Right now, it is 0.67. If you look at our pharma industry, I think the average that is currently at this point of time, like from our peers, almost 20 companies like very close to us, is close to around 0.6 to 0.7 range, okay? So we are targeting to be around one, which is a very, very good number and very aggressive number."
Regulatory & Quality
- Audit clearances: The facility successfully cleared EUGMP and U.S. FDA audits during the year.
- Backward integration approvals: The backward integration project received all necessary licenses and approvals, clearing the path for commercial production.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Target 20% revenue growth for FY26 | FY26 |
| EBITDA margin expansion | Expand EBITDA margins by 20%; anticipate around 20% margin growth on a conservative basis | FY26 |
| Backward integration margin impact | Material margin improvement from backward integration begins | Starting Q2 FY26 |
| Backward integration revenue | Revenue from last year's backward integration capex starts factoring in | FY26 (from Q2) |
| Ibuprofen volume | Target close to 5,000 tons (vs 2,200 MT in FY25) | FY26 |
| HCQ inventory liquidation | Liquidate INR40 crores of slow-moving HCQ inventory as customers anticipate launch | Next 2-3 months |
| Inventory reduction | Reduce overall inventory level from current elevated position | FY26 |
| New capex deployment | Deploy INR250 crores for capacity expansion in existing and new products | Over next 18 months |
| Asset turnover | Reach asset turnover of 1 (from current 0.67) | No date given |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue | ₹248 cr, +43% YoY |
| Full-year revenue | ₹783 cr, +10% YoY |
| Gross profit | ₹75 cr, +18% YoY |
| Gross margin | 30%, +444 bps YoY |
| Full-year gross margin | 33%, +330 bps YoY |
| EBITDA | ₹41 cr, +21% YoY |
| EBITDA margin | 16% |
| Full-year EBITDA margin | 18% |
| PAT | ₹20 cr, +18% YoY |
| PAT margin | 8% |
| Full-year PAT | ₹69 cr, +39% YoY |
| Anti-inflammatory segment revenue (FY25) | ₹148 cr, +22% YoY |
| ARV segment revenue (FY25) | ₹163 cr, +15% YoY |
| Anti-epileptic segment revenue (FY25) | ₹29 cr, +106% YoY |
| Anti-diabetic segment revenue (FY25) | ₹185 cr, +5% YoY |
| Antierectile dysfunction and other APIs revenue (FY25) | +15% YoY |
| Inventory | ₹285 cr |
| Debt | ₹311 cr, with ₹20 cr annual interest cost |
| Slow-moving inventory (COVID-related) | ₹40 cr |
| Capex spent in FY25 | ₹150 cr |
| Capex plan (next 18 months) | ₹250 cr |
| Investment in SMS Peptides Private Limited | ₹10 cr, in one or more tranches |
| Total asset turnover (FY25) | 0.67 |
| Asset turnover target for new capex | 1 |
| Capacity utilization | 75% to 80% |
| Ibuprofen volume (FY25) | 2,200 MT, vs 1,800 MT in FY24 |
| Ibuprofen volume target (FY26) | ~5,000 tons |
| Ibuprofen regulated-market mix | 40% regulated, 60% domestic and ROW |
| FY26 revenue growth target | 20% |
| FY26 EBITDA margin target | 20% |